The global biopharmaceutical market has experienced significant change over the last decade, with the focus of research and development (R&D) shifting towards specialty therapy areas given higher levels of patient unmet medical need and the identification of discreet patient populations. Confronted with increasing generic and biosimilar competition to former blockbuster drugs following a sweeping wave of patent expiries, greater payer pressure and higher regulatory hurdles, biopharmaceutical manufacturers are turning to specialty therapy areas for a higher certainty of commercial success.
Learn more about why Baird Capital continues to invest in the global biopharmaceutical market, as shown by its recent acquisition of Prescient Healthcare Group.
John DiGiovanni is a Principal at Baird Capital, the global direct private investment arm of Robert W. Baird & Co Incorporated. Andrew Ferguson is a Partner with Baird Capital. Both team members are based in London. Baird Capital Partners Europe Limited is authorized and regulated by the Financial Conduct Authority (registered number 150154).